Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study

Critical Care Medicine

Volumn 36, Issue 4, 2008, Pages 1089-1096

  Chastre, Jean ^a   Wunderink, Richard ^b   Prokocimer, Philippe ^c,d   Lee, Michael ^c   Kaniga, Koné ^c   Friedland, Ian ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d Trius Therapeutics   (United States)

Author keywords

Carbapenem; Doripenem; Imipenem; Ventilator associated pneumonia

Indexed keywords

DORIPENEM; IMIPENEM;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER KOSERI; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; FEMALE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOSIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY SYSTEM; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; VENTILATOR; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

EID: 41649099025     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181691b99     Document Type: Article

References (34)

1. Chastre J, Fagon J-Y: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903
2. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485
3. Safdar N, Dezfulian C, Collard HR, et al: Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med 2005; 33:2184-2193
4. Ranes JL, Gordon SM, Chen P, et al: Predictors of long-term mortality in patients with ventilator-associated pneumonia. Am J Med 2006; 119:897.e13-897.e19
5. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
6. Dupont H, Mentac H, Sollet JP, et al: Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362
7. Fowler RA, Flavin KE, Barr J, et al: Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003; 123:835-844
8. Mueller EW, Hanes SD, Croce MA, et al: Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma 2005; 58:94-101
9. American Thoracic Society and Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
10. Jones RN, Huynh HK, Biedenbach DJ: Activities of doripenem (S-4661) against drugresistant clinical pathogens. Antimicrob Agent Chemother 2004; 48:3136-3140
11. Jones RN, Sader HS, Fritsche TR: Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli and various β-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52:71-74
12. Jones RN, Stillwell MG, Sader HS, et al: Uniformly enhanced activity of doripenem compared to other carbapenems (imipenem, meropenem) when testing P. aeruginosa isolates: results from three continents. Abstr. Int J Infect Dis 2006; 10(Suppl 1):S127-S128
13. Sakyo S, Tomita H, Tanimoto K, et al: Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. The high potency of a new carbapenem doripenem. J Antibiot 2006; 59:220-228
14. Mushtaq S, Ge Y, Livermore DM: Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48:3086-3092
15. Mouton JW, Touzw DJ, Horrevorts AM, et al: Comparative pharmacokinetics of the carbapenems: Clinical implications. Clin Pharmacokinet 2000; 39:185-201
16. Drusano GL: Antimicrobial pharmacodynamics: Critical interactions of "bug and drug." Nat Rev Microbiol 2004; 2:289-300
17. Psathas P, Kuzmission A, Ikeda K, et al: Stability of doripenem for injection (500 mg) in representative infusion fluids and containers. Paper presented at: American Society of Hospital Pharmacists Summer Meeting, July 22, 2007. San Francisco, CA. 57E
18. Merrem (meropenem) [package insert]. Wilmington, DE, AstraZeneca, 2005
19. Primaxin (imipenem and cilastatin for injection) [package insert]. White House Station, NJ, Merck, 2005
20. Luna CM, Blanzaco D, Niederman MS, et al: Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-682
21. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 10:818-829
22. Bhavnani SM, Hammel JP, Cirincione BB, et al: Use of pharmacokinetic- pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49:3944-3947
23. Sun HK, Kuti JL, Nicolau DP: Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program. Crit Care Med 2005; 33:2222-2227
24. Jaccard C, Troillet N, Harbarth S, et al: Prospective randomized comparison of imipenem-cilastin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-2972
25. Kaniga K, Prokocimer P, Llorens L, et al: Prevalence of ESBL and fluoroquinolone-resistant isolates from phase 3 trials of nosocomial pneumonia and their susceptibility to doripenem. Paper presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL. E-265
26. Obritsch MD, Fish DN, MacLaren R, et al: Nosocomial infections due to multidrugresistant Pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy 2005; 25:1353-1364
27. Reinhardt A, Kohler T, Wood P, et al: Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: A longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother 2007; 51:1341-1350
28. Calandra G, Lydick E, Carrigan J, et al: The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials. J Clin Pharmacol 1988; 28:120-127
29. Norrby SR: Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15:87-90
30. Horiuchi M, Kimura M, Tokumura M, et al: Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006; 222:114-124
31. Malafaia O, Umeh O, Jang J: Doripenem versus meropenem for the treatment of complicated intra-abdominal infections. Poster presented at: 46th International Congress on Infectious Diseases (ICAAC), September 27-30, 2006, San Francisco, CA. Poster L-1564b
32. Lucasti C, Jasovich A, Umeh O, et al: Treatment of complicated intra-abdominal infections: Doripenem versus meropenem. Poster presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases, March 31-April 3, 2007, Munich, Germany. Poster P834
33. Naber K, Redman R, Kotey P, et al: Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infection and pyelonephritis. Poster presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases, March 31-April 3, 2007, Munich, Germany. Poster P833
34. Singh N, Rogers P, Atwood CW, et al: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-511